AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇨🇮
DOLUTEGRAVIR SODIUM+LAMIVUDINE+TENOFOVIR DISOPROXIL FUMARATE in Côte d'Ivoire
3 products registered with AIRP — 2 active, 1 expired
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| ACRIPTEGA 50MG/ 300MG/ 300MG COMPRIME PELLICULE BOITE DE 180 | MD/1E0322-0012 | MYLAN LABORATORIES LTD | active | 14 Jun 2027 |
| ACRIPTEGA 50MG/ 300MG/ 300MG COMPRIME PELLICULE BOITE DE 90 | MD/1E0322-0011 | MYLAN LABORATORIES LTD | active | 14 Jun 2027 |
| ACRIPTEGA 50MG/ 300MG/ 300MG COMPRIME PELLICULE BOITE DE 30 | E-2019-0198 | MYLAN LABORATORIES LTD | expired | 5 Feb 2024 |
DOLUTEGRAVIR SODIUM+LAMIVUDINE+TENOFOVIR DISOPROXIL FUMARATE — AIRP Registration Details
AIRP (Côte d'Ivoire) has 3 registered products containing DOLUTEGRAVIR SODIUM+LAMIVUDINE+TENOFOVIR DISOPROXIL FUMARATE, of which 2 are currently active. Data is sourced directly from the official AIRP drug register and refreshed daily.
Track DOLUTEGRAVIR SODIUM+LAMIVUDINE+TENOFOVIR DISOPROXIL FUMARATE registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.